Retatrutide_40mg

Retatrutide peptide 40mg (LY3437943) is an experimental weight-loss drug developed by Eli Lilly and Company. It works by targeting three important hormone receptors in the body: GLP-1, GIP, and glucagon. By acting on these receptors, the medication may help control appetite, increase fat burning, and improve how the body manages metabolism.

In Phase 2 clinical trials, people who received weekly injections of retatrutide experienced significant weight loss. Participants taking the 12 mg dose lost an average of 24.2% of their body weight over 48 weeks. Researchers also reported improvements in blood sugar levels, insulin sensitivity, and blood pressure during the study.

Although the results are promising, some side effects have been reported. The most common include nausea, stomach discomfort, and a faster heart rate. These effects were more noticeable at higher doses.

Retatrutide is still being tested in ongoing clinical studies. Researchers continue to study its safety and effectiveness before seeking approval from the U.S.& U.K Food and Drug Administration. If the trials remain successful, the drug could become an important option for weight-loss treatment in the future. Retatrutide peptide 40mg